Courtney Flaherty

Articles

Tevimbra Plus Chemotherapy May Improve Survival in First-Line ESCC

February 1st 2025

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.

Image of red blood cells over technology circuit boards.

CAR-T Cell Therapy Shows EFS Benefit in Pediatric Leukemia Subset

Courtney Flaherty

December 7th 2024

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

A dark background with an outline of a bladder and a red spot where a tumor would be.

Perioperative Imfinzi, Neoadjuvant Chemo Improves Survival in Muscle-Invasive Bladder Cancer

Courtney Flaherty

September 15th 2024

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible muscle-invasive bladder cancer.

Illustration of a doctor with a mask on, pointing at an image of a pair of lungs.

Olomorasib, Keytruda Combo Is Safe for Lung Cancer Subset

Courtney Flaherty

August 13th 2024

Olomorasib plus Keytruda was proven to be safe and well tolerated for patients with KRAS G12C-mutant non-small cell lung cancer.

High Responses to Jaypirca in Relapsed CLL With BTK Mutations

Courtney Flaherty

December 20th 2023

Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.

No Racial Difference in Recurrence-Free Survival in HR+, HER2- Breast Cancer

Courtney Flaherty

December 7th 2023

Race demonstrated differences in overall survival outcomes, but not for three-year recurrence-free survival in patients with HR-positive, HER2-negative breast cancer, according to data.